Legacy Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.16M | Buy |
16,549
+1,322
| +9% | +$284K | 0.39% | 41 |
|
|
2026
Q1 | $3.31M | Sell |
15,227
-425
| -3% | -$94.3K | 0.39% | 42 |
|
|
2025
Q4 | $3.58M | Buy |
15,652
+951
| +6% | +$217K | 0.38% | 42 |
|
|
2025
Q3 | $3.4M | Buy |
+14,701
| New | +$2.99M | 0.42% | 39 |
|
|
2025
Q2 | – | Sell |
-21,983
| Closed | -$4.61M | – | 19 |
|
|
2025
Q1 | $4.61M | Buy |
21,983
+1,171
| +6% | +$228K | 0.47% | 37 |
|
|
2024
Q4 | $3.7M | Sell |
20,812
-1,085
| -5% | -$199K | 0.36% | 50 |
|
|
2024
Q3 | $4.32M | Buy |
21,897
+2,025
| +10% | +$378K | 0.47% | 39 |
|
|
2024
Q2 | $3.41M | Buy |
19,872
+52
| +0.3% | +$8.61K | 0.41% | 41 |
|
|
2024
Q1 | $3.61M | Buy |
19,820
+769
| +4% | +$133K | 0.46% | 41 |
|
|
2023
Q4 | $2.95M | Sell |
19,051
-1,753
| -8% | -$256K | 0.38% | 56 |
|
|
2023
Q3 | $3.1M | Buy |
20,804
+3,382
| +19% | +$496K | 0.5% | 49 |
|
|
2023
Q2 | $2.35M | Buy |
17,422
+12,244
| +236% | +$1.8M | 0.35% | 69 |
|
|
2023
Q1 | $825K | Buy |
5,178
+184
| +4% | +$28.1K | 0.15% | 111 |
|
|
2022
Q4 | $807K | Buy |
4,994
+214
| +4% | +$32.8K | 0.15% | 104 |
|
|
2022
Q3 | $642K | Sell |
4,780
-278
| -5% | -$39.9K | 0.14% | 100 |
|
|
2022
Q2 | $775K | Buy |
5,058
+271
| +6% | +$41.4K | 0.16% | 88 |
|
|
2022
Q1 | $776K | Buy |
4,787
+2,818
| +143% | +$409K | 0.15% | 90 |
|
|
2021
Q4 | $267K | Sell |
1,969
-195
| -9% | -$23K | 0.1% | 102 |
|
|
2021
Q3 | $233K | Buy |
2,164
+206
| +11% | +$23.5K | 0.09% | 110 |
|
|
2021
Q2 | $221K | Hold |
1,958
| – | – | 0.09% | 114 |
|
|
2021
Q1 | $212K | Buy |
+1,958
| New | +$209K | 0.09% | 112 |
|
|
2019
Q3 | – | Sell |
-1,029
| Closed | -$75K | – | 113 |
|
|
2019
Q2 | $75K | Sell |
1,029
-27
| -3% | -$2.12K | 0.05% | 181 |
|
|
2019
Q1 | $85K | Buy |
+1,056
| New | +$86.4K | 0.03% | 166 |
|
|
2018
Q4 | – | Sell |
-2,322
| Closed | -$220K | – | 112 |
|
|
2018
Q3 | $220K | Buy |
2,322
+1,553
| +202% | +$147K | 0.11% | 129 |
|
|
2018
Q2 | $71K | Buy |
769
+542
| +239% | +$52.9K | 0.05% | 160 |
|
|
2018
Q1 | $21K | Hold |
227
| – | – | 0.02% | 210 |
|
|
2017
Q4 | $21K | Buy |
227
+80
| +54% | +$7.54K | 0.02% | 183 |
|
|
2017
Q3 | $13K | Buy |
+147
| New | +$11.2K | 0.01% | 192 |
|
Other funds holding ABBV
Legacy Advisors's ABBV Position: Q2 2026 in Review
Legacy Advisors increased its AbbVie (ABBV) stake by 8.7% in Q2 2026, buying an estimated $284K and bringing the position to 16,549 shares worth $4.16M. The position accounts for 0.39% of the portfolio, ranked #41.
Legacy Advisors first reported a position in ABBV in Q3 2017 and has held it in 28 quarters since. The position peaked at $4.61M in Q1 2025. 4,195 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Legacy Advisors held 16,549 shares of AbbVie worth $4.16M as of Q2 2026.
- Legacy Advisors bought 1,322 AbbVie shares in Q2 2026, an estimated $284K.
- AbbVie made up 0.39% of Legacy Advisors's portfolio in Q2 2026, its #41 holding.
- Legacy Advisors first reported a position in AbbVie in Q3 2017 and has held it in 28 quarters since.
- Legacy Advisors's AbbVie position peaked at $4.61M in Q1 2025.
- 4,195 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Legacy Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.